8-K Announcements
6Material company update
Apr 10, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Feb 26, 2026·SEC
C4 Therapeutics, Inc.(CCCC)Earnings, Financials & Key Ratios
CCCC•NASDAQ
$2.93
$243M mkt cap·Price updated May 6, 2026
AboutC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$36M+1.0%
- EBITDA-$103M+13.0%
- Net Income-$105M+0.3%
- EPS (Diluted)-1.27+16.4%
- Gross Margin77.81%-22.2%
- EBITDA Margin-285.23%+13.8%
- Operating Margin-290.68%+13.5%
- Net Margin-292.08%+1.3%
- ROE-44.44%+2.5%
- ROIC-33.48%+22.2%
- Debt/Equity0.23-23.2%
CCCC Key Insights
C4 Therapeutics, Inc. (CCCC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 19.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CCCC Price & Volume
C4 Therapeutics, Inc. (CCCC) stock price & volume — 10-year historical chart
Loading chart...
CCCC Growth Metrics
C4 Therapeutics, Inc. (CCCC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years1.61%
3 Years4.95%
TTM1.02%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.93%
Return on Capital
10 Years-29.41%
5 Years-32.05%
3 Years-36.42%
Last Year-33.15%
CCCC Recent Earnings
C4 Therapeutics, Inc. (CCCC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 26, 2026EPS
$0.18
Est $0.31
+41.9%
Revenue
$11M
Est $5M
+104.2%
Q4 2025
Nov 6, 2025EPS
$0.44
Est $0.47
+6.4%
Revenue
$11M
Est $4M
+150.7%
Q3 2025
Aug 7, 2025EPS
$0.37
Est $0.38
+2.6%
Revenue
$6M
Est $7M
-5.0%
Q2 2025
May 7, 2025EPS
$0.37
Est $0.48
+22.9%
Revenue
$7M
Est $4M
+104.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.18vs $0.31+41.9% | $11Mvs $5M+104.2% |
| Q4 2025 | Nov 6, 2025 | $0.44vs $0.47+6.4% | $11Mvs $4M+150.7% |
| Q3 2025 | Aug 7, 2025 | $0.37vs $0.38+2.6% | $6Mvs $7M-5.0% |
| Q2 2025 | May 7, 2025 | $0.37vs $0.48+22.9% | $7Mvs $4M+104.5% |
Based on last 12 quarters of dataView full earnings history →
CCCC Peer Comparison
C4 Therapeutics, Inc. (CCCC) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 VRTX | 108.78B | 427.65 | 27.91 | 9.57% | 35.4% | 23.93% | 0.21 | |
 AUPH | 2.15B | 16.25 | 7.85 | 20.38% | 101.47% | 49.4% | 0.13 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 |
Compare CCCC vs Peers
C4 Therapeutics, Inc. (CCCC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CCCC Income Statement
C4 Therapeutics, Inc. (CCCC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 19.36M | 21.38M | 33.2M | 45.78M | 31.1M | 20.76M | 35.58M | 35.95M |
| Revenue Growth % | - | 10.42% | 55.25% | 37.93% | -32.08% | -33.25% | 71.44% | 1.02% |
| Cost of Goods Sold | 28.59M | 0 | 78.44M | 0 | 0 | 7.74M | 0 | 7.97M |
| COGS % of Revenue | 147.66% | - | 236.3% | - | - | 37.28% | - | 22.19% |
| Gross Profit | -9.23M▲ 0% | 21.38M▲ 331.7% | -45.24M▼ 311.6% | 45.78M▲ 201.2% | 31.1M▼ 32.1% | 13.02M▼ 58.1% | 35.58M▲ 173.3% | 27.97M▼ 21.4% |
| Gross Margin % | -47.66% | 100% | -136.3% | 100% | 100% | 62.72% | 100% | 77.81% |
| Gross Profit Growth % | - | 331.7% | -311.61% | 201.19% | -32.08% | -58.13% | 173.32% | -21.39% |
| Operating Expenses | 35.75M | 56.83M | 15.2M | 127.92M | 160.63M | 152.05M | 155.2M | 132.46M |
| OpEx % of Revenue | 184.64% | 265.81% | 45.8% | 279.39% | 516.56% | 732.56% | 436.15% | 368.49% |
| Selling, General & Admin | 7.16M | 8.77M | 15.2M | 33.25M | 42.79M | 42.08M | 42.12M | 36.2M |
| SG&A % of Revenue | 36.98% | 41.04% | 45.8% | 72.63% | 137.6% | 202.74% | 118.38% | 100.69% |
| Research & Development | 28.59M | 48.06M | 78.44M | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
| R&D % of Revenue | 147.66% | 224.77% | 236.3% | 206.76% | 378.96% | 567.09% | 310.92% | 289.98% |
| Other Operating Expenses | -7K | 0 | -78.44M | 0 | 0 | -7.74M | 2.44M | -7.97M |
| Operating Income | -16.39M▲ 0% | -35.45M▼ 116.3% | -60.45M▼ 70.5% | -82.13M▼ 35.9% | -129.53M▼ 57.7% | -139.03M▼ 7.3% | -119.61M▲ 14.0% | -104.49M▲ 12.6% |
| Operating Margin % | -84.64% | -165.81% | -182.1% | -179.39% | -416.56% | -669.84% | -336.15% | -290.68% |
| Operating Income Growth % | - | -116.32% | -70.51% | -35.87% | -57.71% | -7.33% | 13.97% | 12.64% |
| EBITDA | -12.82M | -33.86M | -58.83M | -80.64M | -127.86M | -131.29M | -117.8M | -102.53M |
| EBITDA Margin % | -66.18% | -158.35% | -177.23% | -176.13% | -411.17% | -632.56% | -331.04% | -285.23% |
| EBITDA Growth % | - | -164.18% | -73.77% | -37.07% | -58.55% | -2.69% | 10.28% | 12.96% |
| D&A (Non-Cash Add-back) | 3.57M | 1.59M | 1.62M | 1.49M | 1.68M | 7.74M | 1.82M | 1.96M |
| EBIT | -16.39M | -33.3M | -60.45M | -81.75M | -125.96M | -129.84M | -105.19M | -104.87M |
| Net Interest Income | 685K | 1.83M | -836K | -1.76M | 1.36M | 8.44M | 14.43M | 0 |
| Interest Income | 685K | 1.83M | 393K | 387K | 3.58M | 9.81M | 14.43M | 0 |
| Interest Expense | 0 | 0 | 1.23M | 2.15M | 2.22M | 1.37M | 0 | 0 |
| Other Income/Expense | 678K | 2.16M | -5.26M | -1.76M | 1.36M | 7.82M | 14.43M | -384K |
| Pretax Income | -15.71M▲ 0% | -33.3M▼ 111.9% | -65.71M▼ 97.4% | -83.89M▼ 27.7% | -128.18M▼ 52.8% | -131.21M▼ 2.4% | -105.19M▲ 19.8% | -104.87M▲ 0.3% |
| Pretax Margin % | -81.14% | -155.72% | -197.95% | -183.23% | -412.19% | -632.17% | -295.6% | -291.74% |
| Income Tax | 0 | 804K | 626K | 0 | 0 | 1.28M | 131K | 121K |
| Effective Tax Rate % | 0% | -2.41% | -0.95% | 0% | 0% | -0.98% | -0.12% | -0.12% |
| Net Income | -15.71M▲ 0% | -34.1M▼ 117.0% | -66.33M▼ 94.5% | -83.89M▼ 26.5% | -128.18M▼ 52.8% | -132.49M▼ 3.4% | -105.32M▲ 20.5% | -104.99M▲ 0.3% |
| Net Margin % | -81.14% | -159.48% | -199.83% | -183.23% | -412.19% | -638.34% | -295.96% | -292.08% |
| Net Income Growth % | - | -117.04% | -94.54% | -26.47% | -52.79% | -3.37% | 20.51% | 0.31% |
| Net Income (Continuing) | -15.71M | -34.1M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M | -104.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.06▲ 0% | -0.79▲ 25.5% | -1.54▼ 94.9% | -1.82▼ 18.2% | -2.62▼ 44.0% | -2.67▼ 1.9% | -1.52▲ 43.1% | -1.27▲ 16.4% |
| EPS Growth % | - | 25.47% | -94.94% | -18.18% | -43.96% | -1.91% | 43.07% | 16.45% |
| EPS (Basic) | -1.06 | -0.79 | -1.54 | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 |
| Diluted Shares Outstanding | 42.09M | 42.99M | 43.06M | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
| Basic Shares Outstanding | 14.79M | 42.99M | 43.06M | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CCCC Balance Sheet
C4 Therapeutics, Inc. (CCCC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 123.53M | 96.77M | 381.01M | 325.69M | 287.56M | 271.19M | 257.77M | 258.11M |
| Cash & Short-Term Investments | 36.31M | 90.55M | 371.69M | 309.28M | 276.15M | 253.68M | 244.9M | 248.54M |
| Cash Only | 36.31M | 90.55M | 181.73M | 76.12M | 29.75M | 126.59M | 55.5M | 74.6M |
| Short-Term Investments | 0 | 0 | 189.96M | 233.16M | 246.4M | 127.09M | 189.41M | 173.93M |
| Accounts Receivable | 86.44M | 4.62M | 4.48M | 5.72M | 1.47M | 11.8M | 3.1M | 2.4M |
| Days Sales Outstanding | 1.63K | 78.92 | 49.3 | 45.57 | 17.29 | 207.49 | 31.82 | 24.38 |
| Inventory | 0 | 0 | 0 | 0 | -60.96M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 70.89M | 5.71M | 9.76M | 7.17M |
| Total Non-Current Assets | 22.96M | 21.49M | 19.13M | 181.08M | 143.28M | 105.26M | 91.83M | 100.97M |
| Property, Plant & Equipment | 20.38M | 18.92M | 16.55M | 35.05M | 77.52M | 71.09M | 63.38M | 45.28M |
| Fixed Asset Turnover | 0.95x | 1.13x | 2.01x | 1.31x | 0.40x | 0.29x | 0.56x | 0.79x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 2.58M | 0 | 0 | 142.2M | 60.96M | 28.01M | 22.36M | 0 |
| Other Non-Current Assets | 0 | 2.58M | 2.58M | 3.82M | 4.8M | 6.17M | 6.1M | 55.69M |
| Total Assets | 146.49M▲ 0% | 118.26M▼ 19.3% | 400.14M▲ 238.4% | 506.76M▲ 26.6% | 430.84M▼ 15.0% | 376.45M▼ 12.6% | 349.6M▼ 7.1% | 359.07M▲ 2.7% |
| Asset Turnover | 0.13x | 0.18x | 0.08x | 0.09x | 0.07x | 0.06x | 0.10x | 0.10x |
| Asset Growth % | - | -19.27% | 238.35% | 26.65% | -14.98% | -12.62% | -7.13% | 2.71% |
| Total Current Liabilities | 23.95M | 33.64M | 43.85M | 51.25M | 44.55M | 42.77M | 45.18M | 33.03M |
| Accounts Payable | 1.15M | 5.38M | 5.68M | 4.51M | 1.17M | 1.45M | 1.33M | 858K |
| Days Payables Outstanding | 14.73 | - | 26.44 | - | - | 68.22 | - | 39.27 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 2.29M | 0 | 0 | 6.37M |
| Deferred Revenue (Current) | 19.11M | 20.7M | 27.6M | 31.8M | 16.62M | 15.47M | 18.71M | 12.49M |
| Other Current Liabilities | 1.26M | 3.33M | 4.19M | 5.5M | 3.11M | 9.39M | 9.3M | 13.31M |
| Current Ratio | 5.16x | 2.88x | 8.69x | 6.36x | 6.46x | 6.34x | 5.71x | 7.81x |
| Quick Ratio | 5.16x | 2.88x | 8.69x | 6.36x | 7.82x | 6.34x | 5.71x | 7.81x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 202.29M | 196.58M | 75.5M | 65.91M | 97.06M | 87.57M | 88.44M | 69.46M |
| Long-Term Debt | 0 | 0 | 10.05M | 10.77M | 9.2M | 0 | 0 | 0 |
| Capital Lease Obligations | 13.75M | 12.87M | 11.83M | 30.78M | 70.97M | 65.76M | 59.98M | 53.62M |
| Deferred Tax Liabilities | -13.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 111M | 111M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 226.24M | 230.22M | 119.35M | 117.16M | 141.61M | 130.34M | 133.62M | 102.49M |
| Total Debt | 14.48M | 13.75M | 22.92M | 42.88M | 87.15M | 70.98M | 65.76M | 59.98M |
| Net Debt | -21.83M | -76.8M | -158.81M | -33.24M | 57.4M | -55.61M | 10.26M | -14.62M |
| Debt / Equity | - | - | 0.08x | 0.11x | 0.30x | 0.29x | 0.30x | 0.23x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -49.19x | -38.11x | -56.84x | -94.57x | - | - |
| Total Equity | -79.75M▲ 0% | -111.96M▼ 40.4% | 280.79M▲ 350.8% | 389.61M▲ 38.8% | 289.23M▼ 25.8% | 246.11M▼ 14.9% | 215.99M▼ 12.2% | 256.59M▲ 18.8% |
| Equity Growth % | - | -40.39% | 350.79% | 38.75% | -25.76% | -14.91% | -12.24% | 18.8% |
| Book Value per Share | -1.89 | -2.60 | 6.52 | 8.46 | 5.92 | 4.96 | 3.11 | 3.10 |
| Total Shareholders' Equity | -79.75M | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M | 215.99M | 256.59M |
| Common Stock | 1K | 0 | 4K | 5K | 5K | 6K | 7K | 9K |
| Retained Earnings | -83.39M | -117.49M | -183.82M | -267.71M | -395.89M | -528.38M | -633.7M | -738.69M |
| Treasury Stock | -6.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.5M | 0 | 13K | -775K | -4.14M | -127K | 53K | 50K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CCCC Cash Flow Statement
C4 Therapeutics, Inc. (CCCC) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.98M | 55.61M | -67.25M | -86.97M | -105.94M | -106.84M | -65.16M | -98.69M |
| Operating CF Margin % | -87.69% | 260.11% | -202.59% | -189.94% | -340.68% | -514.73% | -183.11% | -274.55% |
| Operating CF Growth % | - | 427.51% | -220.92% | -29.32% | -21.82% | -0.85% | 39.01% | -51.47% |
| Net Income | -15.71M | -34.1M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M | -104.99M |
| Depreciation & Amortization | 1.27M | 1.59M | 1.62M | 1.49M | 1.68M | 1.88M | 1.82M | 1.96M |
| Stock-Based Compensation | 582K | 1.64M | 3.43M | 21.51M | 30.02M | 27.23M | 29.66M | 19.1M |
| Deferred Taxes | 66K | 350K | 5.58M | 1.88M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.37M | 1.14M | 1.63M | 2.13M | 7.32M | 3.48M | 1.03M | 14.52M |
| Working Capital Changes | -5.56M | 84.98M | -13.18M | -30.09M | -16.78M | -6.94M | 7.65M | -29.28M |
| Change in Receivables | -84.94M | 81.81M | 139K | -1.23M | 4.24M | -10.33M | 8.7M | 701K |
| Change in Inventory | -2.22M | 2.17M | -1.58M | -2.63M | 0 | 0 | 0 | 0 |
| Change in Payables | 578K | 4.23M | 467K | -1.18M | -3.33M | 273K | -119K | -468K |
| Cash from Investing | 36.92M | -1.62M | -190.5M | -189.34M | 58.42M | 158.35M | -51.27M | -8.6M |
| Capital Expenditures | -2.69M | -1.35M | -650K | -1.28M | -5.5M | -1.71M | -180K | -607K |
| CapEx % of Revenue | 13.89% | 6.31% | 1.96% | 2.79% | 17.67% | 8.23% | 0.51% | 1.69% |
| Acquisitions | 0 | 63K | 189.85M | 188.06M | -63.92M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 39.61M | 0 | -189.85M | -188.06M | 63.92M | 0 | 0 | 0 |
| Cash from Financing | 1.96M | 244K | 348.93M | 171.4M | 1.15M | 45.49M | 45.34M | 126.4M |
| Debt Issued (Net) | 0 | 0 | 11.97M | 0 | 0 | -12.5M | 0 | 0 |
| Equity Issued (Net) | 2.02M | -30K | 340.4M | 169.47M | 777K | 57.56M | 44.18M | 126.13M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -63K | -30K | -194K | 0 | 0 | -110K | -194K | -193K |
| Other Financing | -63K | 274K | -3.45M | 1.94M | 370K | 426K | 1.16M | 274K |
| Net Change in Cash | 21.9M▲ 0% | 54.24M▲ 147.7% | 91.18M▲ 68.1% | -104.9M▼ 215.1% | -46.37M▲ 55.8% | 97M▲ 309.2% | -71.09M▼ 173.3% | 19.1M▲ 126.9% |
| Free Cash Flow | -19.67M▲ 0% | 54.27M▲ 375.9% | -67.9M▼ 225.1% | -88.24M▼ 30.0% | -111.44M▼ 26.3% | -108.55M▲ 2.6% | -65.34M▲ 39.8% | -99.3M▼ 52.0% |
| FCF Margin % | -101.58% | 253.8% | -204.55% | -192.73% | -358.36% | -522.96% | -183.61% | -276.24% |
| FCF Growth % | - | 375.88% | -225.12% | -29.96% | -26.28% | 2.59% | 39.81% | -51.98% |
| FCF per Share | -0.47 | 1.26 | -1.58 | -1.92 | -2.28 | -2.19 | -0.94 | -1.20 |
| FCF Conversion (FCF/Net Income) | 1.08x | -1.63x | 1.01x | 1.04x | 0.83x | 0.81x | 0.62x | 0.94x |
| Interest Paid | 0 | 0 | 820K | 0 | 0 | 990K | 0 | 0 |
| Taxes Paid | 0 | 1.09M | 143K | 0 | 0 | 1M | 0 | 0 |
CCCC Key Ratios
C4 Therapeutics, Inc. (CCCC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -78.58% | -25.03% | -37.76% | -49.5% | -45.58% | -44.44% |
| Return on Invested Capital (ROIC) | - | - | -37.17% | -25.76% | -27.64% | -38.83% | -43.05% | -33.48% |
| Gross Margin | -47.66% | 100% | -136.3% | 100% | 100% | 62.72% | 100% | 77.81% |
| Net Margin | -81.14% | -159.48% | -199.83% | -183.23% | -412.19% | -638.34% | -295.96% | -292.08% |
| Debt / Equity | - | - | 0.08x | 0.11x | 0.30x | 0.29x | 0.30x | 0.23x |
| Interest Coverage | - | - | -49.19x | -38.11x | -56.84x | -94.57x | - | - |
| FCF Conversion | 1.08x | -1.63x | 1.01x | 1.04x | 0.83x | 0.81x | 0.62x | 0.94x |
| Revenue Growth | - | 10.42% | 55.25% | 37.93% | -32.08% | -33.25% | 71.44% | 1.02% |
CCCC SEC Filings & Documents
C4 Therapeutics, Inc. (CCCC) SEC filings — annual & quarterly reports (10-K, 10-Q)
CCCC Frequently Asked Questions
C4 Therapeutics, Inc. (CCCC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
C4 Therapeutics, Inc. (CCCC) reported $35.9M in revenue for fiscal year 2025. This represents a 86% increase from $19.4M in 2018.
C4 Therapeutics, Inc. (CCCC) grew revenue by 1.0% over the past year. Growth has been modest.
C4 Therapeutics, Inc. (CCCC) reported a net loss of $105.0M for fiscal year 2025.
Dividend & Returns
C4 Therapeutics, Inc. (CCCC) has a return on equity (ROE) of -44.4%. Negative ROE indicates the company is unprofitable.
C4 Therapeutics, Inc. (CCCC) had negative free cash flow of $99.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More CCCC
C4 Therapeutics, Inc. (CCCC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates